Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(1):107–113. doi: 10.1038/bjc.1997.344

Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations.

K Itoh 1, Y Sasaki 1, H Fujii 1, T Ohtsu 1, H Wakita 1, T Igarashi 1, K Abe 1
PMCID: PMC2223787  PMID: 9218741

Abstract

We attempted to characterize the motivation, comprehension and expectations of patients who had given informed consent to participate in phase I trials of anti-cancer agents at the National Cancer Center of Japan. Thirty-three patients were given a simple multiple-choice questionnaire and asked to return it at a later date. The completed survey was returned by 32 patients. The patients were surveyed before they had received any investigational phase I agents. Nineteen per cent of patients were motivated to participate in the phase I trials by the possibility of therapeutic benefit, 9% because participation seemed a better choice than no treatment and only 6% for altruistic reasons. Most patients comprehended the major features of a phase I trial, namely its investigational nature, the unknown effects of the agent investigated and the unclear benefit to the patients themselves. Fifty-nine per cent of the patients anticipated that they might suffer severe or life-threatening side-effects if they participated in the phase I trial, and 43% were able to indicate accurately the purpose of the phase I trial as a dose determination study. Although only a minority of the patients indicated that their motivation to participate was possible treatment benefit to themselves, when answering questions regarding expectations, more than half indicated that there might be personal benefits of varying degrees by participation.

Full text

PDF
107

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cassileth B. R., Zupkis R. V., Sutton-Smith K., March V. Informed consent -- why are its goals imperfectly realized? N Engl J Med. 1980 Apr 17;302(16):896–900. doi: 10.1056/NEJM198004173021605. [DOI] [PubMed] [Google Scholar]
  2. Daugherty C., Ratain M. J., Grochowski E., Stocking C., Kodish E., Mick R., Siegler M. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995 May;13(5):1062–1072. doi: 10.1200/JCO.1995.13.5.1062. [DOI] [PubMed] [Google Scholar]
  3. Decoster G., Stein G., Holdener E. E. Responses and toxic deaths in phase I clinical trials. Ann Oncol. 1990;1(3):175–181. doi: 10.1093/oxfordjournals.annonc.a057716. [DOI] [PubMed] [Google Scholar]
  4. Estey E., Hoth D., Simon R., Marsoni S., Leyland-Jones B., Wittes R. Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep. 1986 Sep;70(9):1105–1115. [PubMed] [Google Scholar]
  5. Fukaura A., Tazawa H., Nakajima H., Adachi M. Do-not-resuscitate orders at a teaching hospital in Japan. N Engl J Med. 1995 Sep 21;333(12):805–808. doi: 10.1056/NEJM199509213331218. [DOI] [PubMed] [Google Scholar]
  6. Itoh K., Sasaki Y., Miyata Y., Fujii H., Ohtsu T., Wakita H., Igarashi T., Abe K. Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan. Cancer Chemother Pharmacol. 1994;34(6):451–454. doi: 10.1007/BF00685653. [DOI] [PubMed] [Google Scholar]
  7. Kodish E., Stocking C., Ratain M. J., Kohrman A., Siegler M. Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons. J Clin Oncol. 1992 Nov;10(11):1810–1816. doi: 10.1200/JCO.1992.10.11.1810. [DOI] [PubMed] [Google Scholar]
  8. Lavelle-Jones C., Byrne D. J., Rice P., Cuschieri A. Factors affecting quality of informed consent. BMJ. 1993 Apr 3;306(6882):885–890. doi: 10.1136/bmj.306.6882.885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lipsett M. B. On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA. 1982 Aug 27;248(8):941–942. [PubMed] [Google Scholar]
  10. Mick R., Lane N., Daugherty C., Ratain M. J. Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst. 1994 Nov 16;86(22):1685–1693. doi: 10.1093/jnci/86.22.1685. [DOI] [PubMed] [Google Scholar]
  11. Penman D. T., Holland J. C., Bahna G. F., Morrow G., Schmale A. H., Derogatis L. R., Carnrike C. L., Jr, Cherry R. Informed consent for investigational chemotherapy: patients' and physicians' perceptions. J Clin Oncol. 1984 Jul;2(7):849–855. doi: 10.1200/JCO.1984.2.7.849. [DOI] [PubMed] [Google Scholar]
  12. Penta J. S., Rosner G. L., Trump D. L. Choice of starting dose and escalation for phase I studies of antitumor agents. Cancer Chemother Pharmacol. 1992;31(3):247–250. doi: 10.1007/BF00685555. [DOI] [PubMed] [Google Scholar]
  13. Ratain M. J., Mick R., Schilsky R. L., Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20;85(20):1637–1643. doi: 10.1093/jnci/85.20.1637. [DOI] [PubMed] [Google Scholar]
  14. Rodenhuis S., van den Heuvel W. J., Annyas A. A., Koops H. S., Sleijfer D. T., Mulder N. H. Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol. 1984 Apr;20(4):457–462. doi: 10.1016/0277-5379(84)90229-3. [DOI] [PubMed] [Google Scholar]
  15. Tobias J. S., Houghton J. Is informed consent essential for all chemotherapy studies? Eur J Cancer. 1994;30A(7):897–899. doi: 10.1016/0959-8049(94)90107-4. [DOI] [PubMed] [Google Scholar]
  16. Tomamichel M., Sessa C., Herzig S., de Jong J., Pagani O., Willems Y., Cavalli F. Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients. Ann Oncol. 1995 Apr;6(4):363–369. doi: 10.1093/oxfordjournals.annonc.a059185. [DOI] [PubMed] [Google Scholar]
  17. Von Hoff D. D., Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs. 1991 Feb;9(1):115–122. doi: 10.1007/BF00194562. [DOI] [PubMed] [Google Scholar]
  18. Willems Y., Sessa C. Informing patients about phase I trials--how should it be done? Acta Oncol. 1989;28(1):106–107. doi: 10.3109/02841868909111191. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES